Table 2.

Associations between telomere lengths and pancreatic cancer in cases and controls from the Mayo Clinic SPORE patient registry

Age adjustedMultivariable adjusted
Telomere lengthPercentileOR (95% CI)OR (95% CI)
4,18411.46 (1.16–1.84)1.47 (1.11–1.95)
4,354101.33 (1.12–1.56)1.33 (1.09–1.63)
4,524201.21 (1.08–1.34)1.21 (1.06–1.38)
4,676301.11 (1.05–1.19)1.11 (1.03–1.20)
4,799401.05 (1.02–1.08)1.05 (1.01–1.09)
4,911501.00 (Reference)1.00 (Reference)
5,043600.95 (0.92–0.98)0.95 (0.91–0.99)
5,312700.86 (0.79–0.94)0.87 (0.78–0.96)
5,718800.78 (0.67–0.91)0.78 (0.65–0.95)
6,520900.72 (0.56–0.92)0.72 (0.53–0.98)
7,823950.77 (0.54–1.08)0.77 (0.50–1.20)
11,740991.18 (0.66–2.12)1.26 (0.61–2.59)
27,7231004.09 (1.06–15.72)2.87 (0.55–14.91)

NOTE: Multivariable ORs adjusted for age, sex, race, BMI, diabetes status, and fasting blood glucose. The reference category (in bold) is 4,911 base pairs, the median telomere length in the nondiabetic control group.